SCHEMBL4127845

SCHEMBL4127845

CCCc1ccc(NC(=O)Nc2ccc(OC)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SAE1 Q9UBE0 1/20 0.73
UBA2 Q9UBT2 1/20 0.73
ABCG2 Q9UNQ0 2/20 0.72
SMN1; SMN2 Q16637 5/20 0.71
RAB9A P51151 3/20 0.71
NPC1 O15118 2/20 0.71
KDM4E B2RXH2 2/20 0.68
POLB P06746 1/20 0.68
FPR2 P25090 4/20 0.62
CNR1 P21554 1/20 0.62
MAPT P10636 3/20 0.61
ALDH1A1 P00352 1/20 0.61
HIF1A Q16665 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
PKM P14618 1/20 0.59
TP53 P04637 1/20 0.58
ESR2 Q92731 1/20 0.58
NOX1 Q9Y5S8 1/20 0.58
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19234762 0.91 SAE1 (0.69) SAE1UBA2ABCG2SMN1; SMN2RAB9A
SCHEMBL15093809 0.88 HRH3 (0.65) SAE1UBA2ABCG2RAB9ANPC1
SCHEMBL8866830 0.87 SAE1 (0.73) SAE1UBA2ABCG2SMN1; SMN2RAB9A
SCHEMBL8866824 0.87 SAE1 (0.73) SAE1UBA2ABCG2SMN1; SMN2RAB9A
SCHEMBL4121995 0.87 SAE1 (0.78) SAE1UBA2SMN1; SMN2RAB9ANPC1
SCHEMBL4117832 0.86 MAPT (0.69) ABCG2SMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL4110520 0.86 MAPT (0.80) ABCG2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL11092496 0.84 RAB9A (1.00) SAE1UBA2SMN1; SMN2RAB9ANPC1
SCHEMBL14462302 0.83 SAE1 (0.78) SAE1UBA2SMN1; SMN2RAB9ANPC1
SCHEMBL4106216 0.83 RAB9A (0.67) ABCG2SMN1; SMN2RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 SAE1 2238/4885UBA2 318/4885ABCG2 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.